Targets and targeting of immunometabolism in chronic PM2.5 exposure
慢性 PM2.5 暴露中免疫代谢的目标和靶向
基本信息
- 批准号:10349277
- 负责人:
- 金额:$ 40.25万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-02-07 至 2026-11-30
- 项目状态:未结题
- 来源:
- 关键词:ATAC-seqAcute DiseaseAir PollutantsAir PollutionAnimalsAnti-Inflammatory AgentsAntioxidantsArterial Fatty StreakArteriesAtherosclerosisBone Marrow TransplantationCardiometabolic DiseaseCardiovascular DiseasesCellsCholesterolChronicChronic DiseaseDataDietDietary InterventionDisease ProgressionDonor personEnvironmentEnvironmental Risk FactorEnzymesErythroidEtiologyExposure toFatty acid glycerol estersFingerprintFlow CytometryFluorescenceGenesHealthHumanImmuneImpairmentIn VitroInflammationInflammatoryIngestionInhalationInjectionsInterventionLaboratoriesLesionLinkLip structureLipidsMapsMass Spectrum AnalysisMediatingMeta-AnalysisMetabolicMetabolic DiseasesModelingMolecularMorbidity - disease rateMusMyelogenousMyeloid CellsNon-Insulin-Dependent Diabetes MellitusNuclearPTPRC geneParticulatePathway interactionsPharmacologyPhenotypePlasmaPlayPopulationPredispositionPublic HealthRegimenResolutionRiskRisk FactorsRoleSamplingSeriesSerumSorting - Cell MovementStressTestingTherapeutic InterventionTimeUp-RegulationWorkair filterattributable mortalitybasecardiometabolic riskcardiovascular effectscardiovascular risk factorcytokinedietarydietary manipulationepigenomicsfine particlesin vivoirradiationmacrophagemetabolomicsmonocytemortalitynovelnuclear factor-erythroid 2oxidationperipheral bloodresponsesystematic reviewtranscriptome sequencingtranscriptomics
项目摘要
Project Summary
PM2.5 is a leading global risk factor for morbidity and mortality and is the leading environmental factor
implicated in cardiovascular disease. Recent data suggest that PM2.5 and/or traffic-related air pollutants may
play a role in chronic diseases such as Type 2 diabetes mellitus, that may in turn confer susceptibility to
cardiovascular disease and has been the topic of multiple systematic reviews and meta-analysis by us and
others. In a series of studies in animals and humans, we have provided convincing evidence linking PM2.5 to
pathways playing an etiologic role in cardiometabolic disease. Our findings and reviews have fundamentally
shaped the understanding of the effects of PM2.5 and its association with increased risk of cardiometabolic
disease. In particular, our group has demonstrated pro-atherogenic effects of chronic PM2.5 exposure, through
ROS and inflammation dependent pathways. Although our understanding of pathways contributing to
progression of disease has been dramatically enhanced, the mechanisms involved in the resolution of
inflammation and an understanding of how dysregulation of resolution pathways contributes to disease
progression has been limited. Identification of these mechanisms could pave the way for new opportunities to
target non only air pollution mediated cardiovascular risk but other pervasive health risks. Through the
implementation of three specific aims this proposal seeks to: 1) characterize air pollution-induced changes in
inflammation resolution pathways; 2) determine to what extent these pathways overlap with dietary
manipulation; 3) identify potential intervention strategies to promote upregulation of conserved resolution
pathways in response to air pollution-induced inflammation.
项目摘要
PM2.5是全球发病率和死亡率的主要风险因素,也是主要的环境因素
与心血管疾病有关。最近的数据表明,PM2.5和/或与交通有关的空气污染物可能
在2型糖尿病等慢性疾病中发挥作用,这反过来又可能使人对糖尿病易感。
心血管疾病,并已成为我们进行的多项系统综述和荟萃分析的主题,
他人在一系列对动物和人类的研究中,我们提供了令人信服的证据,将PM2.5与
在心脏代谢疾病中发挥病因作用的途径。我们的调查结果和审查从根本上
塑造了对PM2.5的影响及其与心脏代谢风险增加的关系的理解
疾病特别是,我们的研究小组已经证明了慢性PM2.5暴露的促动脉粥样硬化作用,
ROS和炎症依赖性通路。尽管我们对导致
疾病的进展已经大大加快,参与解决的机制,
炎症和了解如何失调的决议途径有助于疾病
进展有限。查明这些机制可以为新的机会铺平道路,
不仅针对空气污染介导的心血管风险,而且针对其他普遍的健康风险。通过
实施三个具体目标这项建议旨在:1)描述空气污染引起的变化,
炎症解决途径; 2)确定这些途径与饮食的重叠程度
3)确定潜在的干预策略,以促进保守的分辨率上调
对空气污染引起的炎症作出反应的途径。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Andrei Maiseyeu其他文献
Andrei Maiseyeu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Andrei Maiseyeu', 18)}}的其他基金
Targets and targeting of immunometabolism in chronic PM2.5 exposure
慢性 PM2.5 暴露中免疫代谢的目标和靶向
- 批准号:
10563199 - 财政年份:2022
- 资助金额:
$ 40.25万 - 项目类别:
Non-racemic metabolic biomaterials for HFpEF
用于 HFpEF 的非外消旋代谢生物材料
- 批准号:
10295348 - 财政年份:2021
- 资助金额:
$ 40.25万 - 项目类别:
Non-racemic metabolic biomaterials for HFpEF
用于 HFpEF 的非外消旋代谢生物材料
- 批准号:
10677638 - 财政年份:2021
- 资助金额:
$ 40.25万 - 项目类别:
Non-racemic metabolic biomaterials for HFpEF
用于 HFpEF 的非外消旋代谢生物材料
- 批准号:
10470026 - 财政年份:2021
- 资助金额:
$ 40.25万 - 项目类别:
Probing Cardiovascular Actions of GLP-1 Using Nanoparticles
使用纳米颗粒探索 GLP-1 的心血管作用
- 批准号:
9914122 - 财政年份:2016
- 资助金额:
$ 40.25万 - 项目类别:
相似海外基金
Improving Acute Disease Management for Patients with Alzheimer's Disease and Related Dementias
改善阿尔茨海默病和相关痴呆症患者的急性疾病管理
- 批准号:
10712647 - 财政年份:2001
- 资助金额:
$ 40.25万 - 项目类别:
INDUCTION OF ACUTE DISEASE IN MACAQUES BY NEF GENE VARIANT OF SIVMAC239
SIVMAC239 的 NEF 基因变体在猕猴中诱导急性疾病
- 批准号:
6247642 - 财政年份:1997
- 资助金额:
$ 40.25万 - 项目类别:
INDUCTION OF ACUTE DISEASE IN MACAQUES BY NEF GENE VARIANT OF SIVMAC239
SIVMAC239 的 NEF 基因变体在猕猴中诱导急性疾病
- 批准号:
3718999 - 财政年份:
- 资助金额:
$ 40.25万 - 项目类别:
Neurophysiological alterations in multiple sclerosis patients during acute disease acivity
多发性硬化症患者急性疾病活动期间的神经生理学变化
- 批准号:
465668867 - 财政年份:
- 资助金额:
$ 40.25万 - 项目类别:
Research Grants
SIVMAC 1NEF ALLELE: LYMPHOCYTE ACTIVATION & ACUTE DISEASE IN MACAQUE MONKEYS
SIVMAC 1NEF 等位基因:淋巴细胞激活
- 批准号:
3719026 - 财政年份:
- 资助金额:
$ 40.25万 - 项目类别:














{{item.name}}会员




